Готові списки джерел за темами / Liquid Biopsy; Precision Oncology; Clinical Management

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій

Добірка наукової літератури з теми "Liquid Biopsy; Precision Oncology; Clinical Management"

Автор: Grafiati

Опубліковано: 7 червня 2025

Оновлено: 2 серпня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Liquid Biopsy; Precision Oncology; Clinical Management".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Liquid Biopsy; Precision Oncology; Clinical Management"

Tan, Wan Ying, Snigdha Nagabhyrava, Olivia Ang-Olson, et al. "Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology." Current Issues in Molecular Biology 46, no. 7 (2024): 6533–65. http://dx.doi.org/10.3390/cimb46070390.

Повний текст джерела

Анотація:

Technological advancements in cell-free DNA (cfDNA) liquid biopsy have triggered exponential growth in numerous clinical applications. While cfDNA-based liquid biopsy has made significant strides in personalizing cancer treatment, the exploration and translation of epigenetics in liquid biopsy to clinical practice is still nascent. This comprehensive review seeks to provide a broad yet in-depth narrative of the present status of epigenetics in cfDNA liquid biopsy and its associated challenges. It highlights the potential of epigenetics in cfDNA liquid biopsy technologies with the hopes of enha

Стилі APA, Harvard, Vancouver, ISO та ін.

Akhoundova, D., J. Mosquera Martinez, L. E. Musmann, et al. "The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer." Journal of Clinical Medicine 9, no. 11 (2020): 3674. http://dx.doi.org/10.3390/jcm9113674.

Повний текст джерела

Анотація:

Liquid biopsy is a rapidly emerging tool of precision oncology enabling minimally invasive molecular diagnostics and longitudinal monitoring of treatment response. For the clinical management of advanced stage lung cancer patients, detection and quantification of circulating tumor DNA (ctDNA) is now widely adopted into clinical practice. Still, interpretation of results and validation of ctDNA-based treatment decisions remain challenging. We report here our experience implementing liquid biopsies into the clinical management of lung cancer. We discuss advantages and limitations of distinct ctD

Стилі APA, Harvard, Vancouver, ISO та ін.

Durole, Payal* S. Waghmare M. Joshi Gangalwar Amey Chavan Siddhesh Chondhe Nikita. "Liquid Biopsies: Revolutionizing Cancer Diagnosis and Prognosis." International Journal of Pharmaceutical Sciences 3, no. 5 (2025): 1724–43. https://doi.org/10.5281/zenodo.15382783.

Повний текст джерела

Анотація:

Liquid biopsy, consisting in the non-invasive analysis of circulating tumor-derived material (the Tumor Circulome), represents an innovative tool in precision oncology to overcome current limitations associated with tissue biopsies. Within the tumor circulome, ctDNA and CTCs are the only components whose clinical application is FDA-cleared. Extracellular vesicles, ctRNA and tumor-educated platelets are relatively novel tumor circulome constituents with promising potential at each stage of cancer management. Here, we discuss the clinical applications of each element of the tumor circulome and t

Стилі APA, Harvard, Vancouver, ISO та ін.

von Felden, Johann, Teresa Garcia-Lezana, Kornelius Schulze, Bojan Losic, and Augusto Villanueva. "Liquid biopsy in the clinical management of hepatocellular carcinoma." Gut 69, no. 11 (2020): 2025–34. http://dx.doi.org/10.1136/gutjnl-2019-320282.

Повний текст джерела

Анотація:

With increasing knowledge on molecular tumour information, precision oncology has revolutionised the medical field over the past years. Liquid biopsy entails the analysis of circulating tumour components, such as circulating tumour DNA, tumour cells or tumour-derived extracellular vesicles, and has thus come as a handy tool for personalised medicine in many cancer entities. Clinical applications under investigation include early cancer detection, prediction of treatment response and molecular monitoring of the disease, for example, to comprehend resistance patterns and clonal tumour evolution.

Стилі APA, Harvard, Vancouver, ISO та ін.

Bertoli, Elisa, Elisa De Carlo, Debora Basile, et al. "Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications." International Journal of Molecular Sciences 24, no. 13 (2023): 10803. http://dx.doi.org/10.3390/ijms241310803.

Повний текст джерела

Анотація:

Tissue biopsy is essential for NSCLC diagnosis and treatment management. Over the past decades, liquid biopsy has proven to be a powerful tool in clinical oncology, isolating tumor-derived entities from the blood. Liquid biopsy permits several advantages over tissue biopsy: it is non-invasive, and it should provide a better view of tumor heterogeneity, gene alterations, and clonal evolution. Consequentially, liquid biopsy has gained attention as a cancer biomarker tool, with growing clinical applications in NSCLC. In the era of precision medicine based on molecular typing, non-invasive genotyp

Стилі APA, Harvard, Vancouver, ISO та ін.

Muinelo-Romay, Laura, Carlos Casas-Arozamena, and Miguel Abal. "Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology." International Journal of Molecular Sciences 19, no. 8 (2018): 2311. http://dx.doi.org/10.3390/ijms19082311.

Повний текст джерела

Анотація:

The identification of new molecular targets and biomarkers associated with high risk of recurrence and response to therapy represents one of the main clinical challenges in the management of advanced disease in endometrial cancer. In this sense, the field of liquid biopsy has emerged as a great revolution in oncology and is considered “the way” to reach personalised medicine. In this review, we discuss the promising but already relatively limited advances of liquid biopsy in endometrial cancer compared to other types of tumours like breast, colorectal or prostate cancer. We present recent data

Стилі APA, Harvard, Vancouver, ISO та ін.

Nagayama, Satoshi, Siew-Kee Low, Kazuma Kiyotani, and Yusuke Nakamura. "Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy." Cancers 13, no. 19 (2021): 4803. http://dx.doi.org/10.3390/cancers13194803.

Повний текст джерела

Анотація:

In the field of colorectal cancer (CRC) treatment, diagnostic modalities and chemotherapy regimens have progressed remarkably in the last two decades. However, it is still difficult to identify minimal residual disease (MRD) necessary for early detection of recurrence/relapse of tumors and to select and provide appropriate drugs timely before a tumor becomes multi-drug-resistant and more aggressive. We consider the leveraging of in-depth genomic profiles of tumors as a significant breakthrough to further improve the overall prognosis of CRC patients. With the recent technological advances in m

Стилі APA, Harvard, Vancouver, ISO та ін.

Lin, Chen, Xuzhu Liu, Bingyi Zheng, Rongqin Ke, and Chi-Meng Tzeng. "Liquid Biopsy, ctDNA Diagnosis through NGS." Life 11, no. 9 (2021): 890. http://dx.doi.org/10.3390/life11090890.

Повний текст джерела

Анотація:

Liquid biopsy with circulating tumor DNA (ctDNA) profiling by next-generation sequencing holds great promise to revolutionize clinical oncology. It relies on the basis that ctDNA represents the real-time status of the tumor genome which contains information of genetic alterations. Compared to tissue biopsy, liquid biopsy possesses great advantages such as a less demanding procedure, minimal invasion, ease of frequent sampling, and less sampling bias. Next-generation sequencing (NGS) methods have come to a point that both the cost and performance are suitable for clinical diagnosis. Thus, profi

Стилі APA, Harvard, Vancouver, ISO та ін.

Tao, Jessica, Jenna VanLiere Canzoniero, Maria Fatteh, et al. "Liquid biopsy-informed precision oncology study to evaluate utility of plasma genomic profiling for therapy selection." Journal of Clinical Oncology 41, no. 16_suppl (2023): TPS1616. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps1616.

Повний текст джерела

Анотація:

TPS1616 Background: Liquid biopsies have enabled a transformation in the management of patients with cancer as they have the potential to detect, characterize, and monitor tumor burden. However, the increasing complexity involved in the integration of genomic data into clinical practice has presented challenges with the practical implementation of liquid biopsies in clinical cancer care. To address these challenges, multidisciplinary teams comprised of experts within oncology, genetics, pathology, and informatics have created Molecular Tumor Boards (MTBs), which can improve clinical outcomes f

Стилі APA, Harvard, Vancouver, ISO та ін.

Fernandes Marques, Joana, Joana Pereira Reis, Gabriela Fernandes, Venceslau Hespanhol, José Carlos Machado, and José Luís Costa. "Circulating Tumor DNA: A Step into the Future of Cancer Management." Acta Cytologica 63, no. 6 (2019): 456–65. http://dx.doi.org/10.1159/000492917.

Повний текст джерела

Анотація:

Liquid biopsy was introduced to the oncology field with the promise of revolutionizing the management of cancer patients, minimizing the exposure to invasive procedures such as tissue biopsy, and providing reliable information regarding therapy response and detection of disease relapse. Despite the significant increase in the number of published studies on circulating tumor DNA (ctDNA) in the past years, the emphasis of most studies is on the development of new technologies or on the clinical utility of ctDNA. This leaves a clear gap of knowledge concerning the biology of ctDNA, such as the fu

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Liquid Biopsy; Precision Oncology; Clinical Management"

MAZZITELLI, CARLOTTA. "CIrculating TUmor CELls (CTCs), circulating tumor DNA (ctDNA) and exosomes (Ex) in breast cancer patients: a prospective study." Doctoral thesis, Università degli studi di Genova, 2021. http://hdl.handle.net/11567/1044956.

Повний текст джерела

Анотація:

Background The translational study CITUCEL aims to correlate the presence of CTCs and ctDNA at different time points with the clinical outcome of BC patients in neo-adjuvant, adjuvant or advanced setting and to compare the mutational profiles of the primary tumor, CTCs and ctDNA in the different settings. Methods CTCs have been characterized and isolated single or in pool with the DEPArray system, after immunologic negative enrichment with antibodies coupled to magnetic beads against common leukocytes and red blood cells antigens, followed by cells labelling with specific antibody for ep

Стилі APA, Harvard, Vancouver, ISO та ін.

Книги з теми "Liquid Biopsy; Precision Oncology; Clinical Management"

Ravegnini, Gloria, Ambra A. Grolla, Marzia Del Re, Sabrina Angelini, and Ron H. van Schaik, eds. Liquid Biopsy as a Tool for Precision Oncology: New Challenges to Assess Clinical Response. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88966-202-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Liquid Biopsy; Precision Oncology; Clinical Management"

Castaneda, Carlos A. "Molecular and Cellular Analyses of Breast Cancers in Real Life." In Improving Oncology Worldwide. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96053-7_10.

Повний текст джерела

Анотація:

AbstractBreast cancer is the most common women’s malignancy. Incorporation of biomarkers of prognosis and prediction of response are needed to improve treatment management. Lectures for immunohistochemistry of estrogen, progesterone, and HER2 receptors as well as Ki67 staining in cancer cells have been incorporated, and their positive cutoffs have periodically been reviewed. Gene expression platforms in tumor lesions as well as germline and somatic mutations have also been included in the practice for treatment selection. Liquid biopsy evaluating circulating tumor cells (CTCs) and circulating

Стилі APA, Harvard, Vancouver, ISO та ін.

Tinhofer, Ingeborg. "The Role of Liquid Biopsies for Monitoring Disease Evolution." In Critical Issues in Head and Neck Oncology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_4.

Повний текст джерела

Анотація:

AbstractBody fluids of cancer patients have attracted increasing attention in biomedical research within the last 15 years since—as so-called liquid biopsies—they represent a non-invasive source of clinically exploitable biomarkers, including circulating tumor cells (CTCs) and cell-free tumor DNA (ctDNA). Assessment of CTCs in peripheral blood from solid cancer patients has proven useful for detection of subclinical disease which otherwise remains invisible for current staging techniques. Based on results from large cohort studies in breast and colon cancer, diagnostic tests for enumeration of

Стилі APA, Harvard, Vancouver, ISO та ін.

Jahan, Marium, Ayesha Rubab, Mohsin Ali, et al. "Circulating Tumor Cells and DNA in Early Diagnosis and Prognosis of Metastatic Cancer." In Cancer Metastasis - Mechanism, Diagnosis, Prognosis and Targeted Therapy [Working Title]. IntechOpen, 2025. https://doi.org/10.5772/intechopen.1008938.

Повний текст джерела

Анотація:

Metastatic cancer remains a major challenge in oncology, often diagnosed late with limited intervention options. This chapter highlights the role of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) as biomarkers for early detection, diagnosis, and prognosis. Liquid biopsy, a non-invasive method, analyzes blood components like CTCs, which provide insights into tumor heterogeneity and metastatic potential, and ctDNA, which reflects genetic mutations and tumor burden. These biomarkers enable real-time tumor monitoring, aiding in understanding progression, treatment response, resid

Стилі APA, Harvard, Vancouver, ISO та ін.

Denninghoff, Valeria, and Maria Jose Serrano. "Liquid Biopsy." In Molecular Diagnostics of Cancer [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.1002519.

Повний текст джерела

Анотація:

New ways of looking at tumor genetics and dynamics have been developed: the Liquid Biopsy (LB), which has been incorporated into clinical practice as a noninvasive analysis of circulating material derived from tumors, which represents an innovative tool in precision oncology and overcomes the current limitations associated with tissue biopsies. An LB is a new tool of great value, constituting a diagnostic, prognostic, and predictive marker. The elements that makeup LB are circulating tumor cells (CTCs) and circulating tumor nucleic acids (ctNA: DNA or RNA) in free cells or contained in exosome

Стилі APA, Harvard, Vancouver, ISO та ін.

Mosoane, Benny, Amanda Skepu, Chrysis Sofianos, Masibulele Nonxuba, Aristotelis Chatziioannou,, and Zodwa Dlamini. "Diagnostic Innovations for Head and Neck Cancers." In Navigating Head and Neck Cancer, edited by Zodwa Dlamini. Oxford University PressNew York, 2025. https://doi.org/10.1093/med/9780197794197.003.0004.

Повний текст джерела

Анотація:

Abstract Head and neck cancers (HNC) encompass heterogeneous malignancies with varied etiologies and clinical behaviors. The complexity of the HNC anatomical regions complicates tumor diagnosis, necessitating clinical, imaging, and laboratory tests for accurate diagnosis. Pathologists frequently confirm distinct neoplasm of HNC using light microscopy, often supplemented by immunohistochemistry (IHC) and molecular testing. The development of precision molecular testing can guide personalized therapies. Advances in radiology enhance HNC diagnosis, staging, and management. Diagnostic imaging esta

Стилі APA, Harvard, Vancouver, ISO та ін.

Sundaresan, Sivapatham, and Palanirasu Rajapriya. "Translational Perspective in Hepatocellular Carcinoma." In Translational Research in Cancer [Working Title]. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.94769.

Повний текст джерела

Анотація:

The burden of liver cancer is higher in Hispanics, African Americans, and Asians. Viral hepatitis (Hepatitis B and Hepatitis C viruses), non-alcoholic steatohepatitis (NASH), and alcoholic liver disease (ALD) are the most common etiological/risk factors for liver cancer. Approximately 80–90% of hepatocellular carcinoma (HCC) occurs in patients with underlying liver cirrhosis. Individuals with advanced cirrhosis represent a high-risk group for liver cancer. To fill the increasing gap between basic science and clinical research, translational research has been developed as an emerging technology

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Liquid Biopsy; Precision Oncology; Clinical Management"

Suchkov, Sergey. "Advancing and Translating Personalized and Precision Medicine in Pediatric Services to secure the human Wellness and Biosafety: Past, Present and Future." In World Conference on Gynecology, Obstetrics, and Pediatrics. Eurasia Conferences, 2025. https://doi.org/10.62422/978-81-981865-0-8-009.

Повний текст джерела

Анотація:

And personalized tumor molecular profiles (tumor biomarkers can be OMICS-profiles that predict therapy response.), tumor disease site and other patient characteristics are then potentially used for determining optimum individualized therapy options. Recent advances in systems biology and cancer pathology have tremendously affected the practice of pathology, gradually transforming it from a morphology-based into a precise molecular-based cancer-related discipline. The improvement of methodology for genomic testing has made it one of the cornerstones of PPM-related cancer medicine (PPO). Various

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!